Cytokinetics, Incorporated (CYTK) Q3 2021 Earnings Call Transcript | The Motley Fool
CYTK earnings call for the period ending September 30, 2021.
Related Articles
The Day Novartis Chose Discovery
How a Swiss pharma giant built the last great corporate research skunkworks – and why that model may never work again.
AI is poised to transform healthcare, but lack of trust, transparency, or modernized consent could impede its progress. | Alicia C. Staley
AI is poised to transform healthcare, but lack of trust, transparency, or modernized consent could impede its progress. In the first article of a new…
ICER Weekly View: Today’s SMA public meeting, more on MFN, & the Sarepta controversy continues
Email from ICER Weekly View View as Webpage Sign up for ICER’s Weekly View Newsletter Weekly View August 1, 2025 From the desk of…
Neuvivo Reaches Alignment with FDA on an Approval Pathway for NP001 to Treat ALS and Announces the Appointment of Biopharmaceutical Expert Dr. John Curnutte to Its Board of Directors
Neuvivo, Inc., a late-stage biopharmaceutical company developing treatments for neurodegenerative disease, today announced it has gained alignment with the U…
Glycerophospholipids in ALS: insights into disease mechanisms and clinical implication – Molecular Neurodegeneration
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease affecting the adult motor system, with no effective treatments available. Despite extensive research efforts, the exact…
The emotion of being heard again: A man with ALS recovers his voice
The University of California develops a brain-computer interface that records neural signals to decipher words, intonation, and rhythm
George Kooymans – A Tribute to the Golden Earring Legend Lost to ALS at 77
George Kooymans – A Tribute to the legendary guitarist and Golden Earring icon, honouring his music legacy and the farewell shows planned in his memory.
Advancing rare disease research and patient advocacy
In the United States, a disease must affect fewer than 200,000 people to be considered rare, but there are more than 8,000 known rare diseases.…
There is no known cure for ALS, but medical tourism exploits desperation for profit
ALS is a progressive and fatal neurological disorder with no known cure. A new clinic offering treatment raises alarms about exploiting those living with ALS.
5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis
A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of the FDA.